The chemical class known as RFPL2 activators encompasses a diverse range of compounds that are recognized for their ability to modulate the ubiquitin-proteasome system, a critical mechanism for protein turnover and regulation within the cell. These activators are characterized by their varied mechanisms of action, which can lead to the upregulation of E3 ubiquitin ligase activity, a category in which RFPL2 is included. The ubiquitin-proteasome pathway is a key cellular process responsible for the degradation of misfolded, damaged, or regulatory proteins. By influencing this pathway, RFPL2 activators can promote the maintenance of cellular homeostasis and the appropriate response to proteostatic stress. These activators can range from small molecule inhibitors of proteasome function to enhancers of autophagy, all of which can result in an increase in the demand for E3 ligase activity to manage the cellular protein load.
RFPL2 activators can also include molecules that inhibit specific enzymes involved in the ubiquitination cascade, such as E1 activating enzymes, leading to an accumulation of ubiquitinated proteins and a subsequent increase in E3 ligase activity to compensate. Additionally, these activators can encompass compounds that stabilize proteins typically marked for degradation, thus indirectly influencing the ubiquitin pathway and E3 ligase function. By affecting upstream regulatory proteins or signaling pathways, such as the NF-κB pathway, these activators can alter the dynamics of protein ubiquitination, leading to changes in RFPL2 activity. The ability of RFPL2 activators to modulate these complex pathways underscores their role in the intricate regulation of protein quality control within the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor that could possibly activate RFPL2 by causing accumulation of ubiquitinated proteins, which may lead to a compensatory increase in E3 ligase activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Another proteasome inhibitor that could possibly activate RFPL2 by leading to an increase in ubiquitinated protein levels and potentially necessitating enhanced E3 ligase function. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
An E1 enzyme inhibitor that could possibly activate RFPL2 by increasing levels of ubiquitinated proteins, potentially enhancing the need for RFPL2 E3 ligase activity. | ||||||
SMER28 | 307538-42-7 | sc-222320 | 10 mg | $173.00 | ||
A small molecule enhancer of rapamycin that could possibly activate RFPL2 by inducing autophagy and thereby affecting ubiquitin-mediated degradation pathways. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Known for its immunomodulatory effects, thalidomide could possibly activate RFPL2 by modulating the ubiquitin ligase activity of the cereblon complex. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
A thalidomide derivative that could possibly activate RFPL2 by modulating cereblon E3 ubiquitin ligase activity, which may have downstream effects on RFPL2. | ||||||
Pomalidomide | 19171-19-8 | sc-364593 sc-364593A sc-364593B sc-364593C sc-364593D sc-364593E | 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $100.00 $143.00 $312.00 $468.00 $1248.00 $1997.00 | 1 | |
Similar to other immunomodulatory drugs, pomalidomide could possibly activate RFPL2 through its effects on cereblon activity. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
As an MDM2 antagonist that stabilizes p53, Nutlin-3 could possibly activate RFPL2 by affecting the ubiquitin-proteasome system and protein turnover. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride, a GSK3 inhibitor, could possibly activate RFPL2 by influencing signaling pathways that intersect with ubiquitin ligase functions. | ||||||
Parthenolide | 20554-84-1 | sc-3523 sc-3523A | 50 mg 250 mg | $81.00 $306.00 | 32 | |
As an NF-κB pathway inhibitor, parthenolide could possibly activate RFPL2 by affecting protein turnover and degradation pathways. | ||||||